Hormone Receptor Status, Tumor Characteristics, and Prognosis: a Prospective Cohort of Breast Cancer Patients

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2007 Jan 24

PMID 17239243

Citations 319

Authors

Lisa K Dunnwald

Mary Anne Rossing

Christopher I Li

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer patients with tumors that are estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive have lower risks of mortality after their diagnosis compared to women with ER- and/or PR-negative disease. However, few studies have evaluated variations in the risks of breast cancer-specific mortality across ER/PR status by either demographic or clinical characteristics.

Methods: Using data from 11 population-based cancer registries that participate in the SEER (Surveillance, Epidemiology, and End Results) program, 155,175 women at least 30 years old with a primary diagnosis of invasive breast carcinoma from 1990 to 2001 were included in the study. Associations between joint hormone receptor status and breast cancer mortality risk within categories of diagnosis age, diagnosis year, race/ethnicity, histologic tumor type, stage, grade, size, and axillary lymph node status were evaluated using the Cox proportional hazards model.

Results: Compared to ER+/PR+ cases, elevations in risk of mortality were observed across all subcategories of age at diagnosis, ranging from 1.2- to 1.5-fold differences for ER+/PR- cases, 1.5- to 2.1-fold differences for ER-/PR+ cases, and 2.1- to 2.6-fold differences for ER-/PR- cases. Greater differences were observed in analyses stratified by grade; among women with low-grade lesions, ER-/PR- patients had a 2.6-fold (95% confidence interval [CI] 1.7 to 3.9) to 3.1-fold (95% CI 2.8 to 3.4) increased risk of mortality compared to ER+/PR+ patients, but among women with high-grade lesions, they had a 2.1-fold (95% CI 1.9 to 2.2) to 2.3-fold (95% CI 1.8 to 2.8) increased risk.

Conclusion: Compared to women with ER+/PR+ tumors, women with ER+/PR-, ER-/PR+, or ER-/PR- tumors experienced higher risks of mortality, which were largely independent of the various demographic and clinical tumor characteristics assessed in this study. The higher relative mortality risks identified among ER-/PR- patients with small or low-grade tumors raise the question of whether there may be a beneficial role for adjuvant chemotherapy in this population.

Citing Articles

The Impact of Progesterone Receptor Status on Survival Outcomes in Metastatic Breast Cancer Patients Treated with First-Line CDK4/6 Inhibitors.

Guliyev M, Guren A, Ozge E, Colak R, Majidova N, Alkan Sen G Cancers (Basel). 2025; 17(4).

PMID: 40002286 PMC: 11853050. DOI: 10.3390/cancers17040693.

Mendelian randomization study identifying immune cell phenotypes associated with breast cancer risk.

Zhang Z, Zhao J, Li Y, Zhang H, Chen Y, Yang L Discov Oncol. 2025; 16(1):205.

PMID: 39969618 PMC: 11839965. DOI: 10.1007/s12672-025-01963-z.

Defining the regulatory logic of breast cancer using single-cell epigenetic and transcriptome profiling.

Regner M, Garcia-Recio S, Thennavan A, Wisniewska K, Mendez-Giraldez R, Felsheim B Cell Genom. 2025; 5(2):100765.

PMID: 39914387 PMC: 11872555. DOI: 10.1016/j.xgen.2025.100765.

Development of metastasis and survival prediction model of luminal and non-luminal breast cancer with weakly supervised learning based on pathomics.

Liu H, Ying L, Song X, Xiang X, Wei S PeerJ. 2025; 13:e18780.

PMID: 39866573 PMC: 11759606. DOI: 10.7717/peerj.18780.

Prognostic prediction for HER2-low breast cancer patients using a novel machine learning model.

Li Y, Yang X, Ma L BMC Cancer. 2024; 24(1):1474.

PMID: 39614188 PMC: 11606213. DOI: 10.1186/s12885-024-13241-2.

References

Anderson W, Chu K, Chatterjee N, Brawley O, Brinton L . Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol. 2001; 19(1):18-27. DOI: 10.1200/JCO.2001.19.1.18. View

Berry D, Cirrincione C, Henderson I, Citron M, Budman D, Goldstein L . Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006; 295(14):1658-67. PMC: 1459540. DOI: 10.1001/jama.295.14.1658. View

Li C, Malone K, Daling J . Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev. 2002; 11(7):601-7. View

. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst. 2002; 94(14):1054-65. DOI: 10.1093/jnci/94.14.1054. View

Cowper D, Kubal J, Maynard C, Hynes D . A primer and comparative review of major US mortality databases. Ann Epidemiol. 2002; 12(7):462-8. DOI: 10.1016/s1047-2797(01)00285-x. View

Li C, Daling J, Malone K . Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol. 2002; 21(1):28-34. DOI: 10.1200/JCO.2003.03.088. View

Bardou V, Arpino G, Elledge R, Osborne C, Clark G . Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003; 21(10):1973-9. DOI: 10.1200/JCO.2003.09.099. View

Goldhirsch A, Wood W, Gelber R, Coates A, Thurlimann B, Senn H . Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003; 21(17):3357-65. DOI: 10.1200/JCO.2003.04.576. View

Smith R, Good B . Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant Breast and Bowel Project and others. Endocr Relat Cancer. 2003; 10(3):347-57. DOI: 10.1677/erc.0.0100347. View

10.

Fisher B, Jeong J, Bryant J, Anderson S, Dignam J, Fisher E . Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004; 364(9437):858-68. DOI: 10.1016/S0140-6736(04)16981-X. View

11.

Parl F, Schmidt B, Dupont W, Wagner R . Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer. 1984; 54(10):2237-42. DOI: 10.1002/1097-0142(19841115)54:10<2237::aid-cncr2820541029>3.0.co;2-v. View

12.

Pegoraro R, Karnan V, Nirmul D, JOUBERT S . Estrogen and progesterone receptors in breast cancer among women of different racial groups. Cancer Res. 1986; 46(4 Pt 2):2117-20. View

13.

Fisher B, Redmond C, Fisher E, Caplan R . Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol. 1988; 6(7):1076-87. DOI: 10.1200/JCO.1988.6.7.1076. View

14.

Allred D, Bustamante M, Daniel C, GASKILL H, Cruz Jr A . Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg. 1990; 125(1):107-13. DOI: 10.1001/archsurg.1990.01410130113018. View

15.

Crowe Jr J, Gordon N, HUBAY C, Shenk R, ZOLLINGER R, Brumberg D . Estrogen receptor determination and long term survival of patients with carcinoma of the breast. Surg Gynecol Obstet. 1991; 173(4):273-8. View

16.

Aaltomaa S, Lipponen P, Eskelinen M, Kosma V, Marin S, Alhava E . Hormone receptors as prognostic factors in female breast cancer. Ann Med. 1991; 23(6):643-8. DOI: 10.3109/07853899109148097. View

17.

DONEGAN W . Prognostic factors. Stage and receptor status in breast cancer. Cancer. 1992; 70(6 Suppl):1755-64. DOI: 10.1002/1097-0142(19920915)70:4+<1755::aid-cncr2820701617>3.0.co;2-g. View

18.

Elledge R, Clark G, Chamness G, Osborne C . Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst. 1994; 86(9):705-12. DOI: 10.1093/jnci/86.9.705. View

19.

Gapstur S, Dupuis J, Gann P, Collila S, WINCHESTER D . Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13,239 cases. Cancer. 1996; 77(8):1465-71. DOI: 10.1002/(SICI)1097-0142(19960415)77:8<1465::AID-CNCR7>3.0.CO;2-B. View

20.

Pichon M, Broet P, Magdelenat H, DELARUE J, Spyratos F, Basuyau J . Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer. 1996; 73(12):1545-51. PMC: 2074541. DOI: 10.1038/bjc.1996.291. View